Here are Siltanen’s preview comments as Herantis reports its H2 results on Thursday 
Herantis Pharma will publish its 2025 results on Thursday, March 5, 2026, and the company’s results announcement can be followed here starting at 10:00 a.m. In the report, we are particularly monitoring how the preparations for the Phase 2 clinical trial of the HER-096 drug candidate are progressing. Funding for the upcoming study has become clearer following the recently announced share issue and EU grant. Any additional information regarding the securing of the remaining funding requirement will also be at the center of the report.